Art. -Nr.: HY-12461

WS6

Kundenbewertung

Based on 1 Customer Validation

WS6 is an IkB kinase and EBP1 inhibitor, with IC₅₀ values of 0.24 nM, 0.21 nM, and 40.48 nM in MV4-11, MOLM13, and K562 cells, respectively. WS6 promotes the proliferation of alpha and beta cells in the pancreas, has antioxidant and anti-inflammatory activities, and can alleviate depression like behavior in rats^[1][2][4].

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.30%
CAS. Nr.: 1421227-53-3
Formel: C₂₉H₃₁F₃N₆O₃
Molecular Weight:568.59

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

WS6 Chemical Structure

CAS. Nr.: 1421227-53-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

EBP1, IkB^[1].

Alle PI3K Isoform-spezifische Produkte anzeigen :

Alle EGFR Isoform-spezifische Produkte anzeigen :

Alle IKK Isoform-spezifische Produkte anzeigen :

In Vitro

WS6 (1 μM, 48 h) stimulates the proliferation of alpha and beta cells in human pancreatic islets while maintaining cell viability and beta cell differentiation phenotype^[1].
WS6 (0-30 μM, 72 h) reduces MYCN protein stability and neuroblastoma tumorigenicity by inhibiting PA2G4 and MYCN protein binding^[3].
WS6 (0-1 μM, 72 h) overcomes drug resistance and kills FLT3-ITD AML primitive cells by targeting FLT3-ITD driven kinase in acute myeloid leukemia (AML)^[4].
WS6 (0.1, 0.5 μM, 15 min) promotes cell proliferation in the cochlea of neonatal mice by activating ERBB2 phosphorylation and PI3K activity, and enhancing EGFR family signaling^[5].
WS6 exhibits better pharmacokinetic characteristics and binding strength with acetylcholinesterase and neurotrophic factors in computer simulations, thus having the potential to treat Alzheimer's disease^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1].

Cell Line:

Human pancreatic beta and alpha cells
Concentration:

1 μM
Incubation Time:

48 h
Result:

Resulted in insulin expression similar to that of the control group islets.

Cell Proliferation Assay^[3].

Cell Line:

Kelly and SK-N-BE (2) - C human neuroblastoma tumor cell lines
Concentration:

0-30 μM
Incubation Time:

2 weeks
Result:

Reduced the number and size of colonies in Kelly and SK-N-BE (2) - C cells.

Cell Cytotoxicity Assay^[4].

Cell Line:

FLT3-ITD AML (MV4-11 and MOLM13), FLT3-wt AML cell (U937 and HL60), CML (K562), T-ALL (Jurkat), lung adenocarcinoma cell (A549)
Concentration:

0-1 μM
Incubation Time:

72 h
Result:

Exhibits significant cytotoxicity towards FLT3-ITD AML (MV4-11 and MOLM13) and CML (K562) cell lines, with IC₅₀ values of 0.24nM, 0.21nM, and 40.48nM, respectively.

Western Blot Analysis^[5].

Cell Line:

MCF-7 cell
Concentration:

0.1、0.5 μM
Incubation Time:

15 min
Result:

Increased p-ERBB2 protein expression in breast cancer cell line MCF-7.

In Vivo

WS6 (2.2 mg/kg; once a day; 28 days; i.p.) alleviates depression like behavior in rats by enhancing GABA signaling and dendritic density in the hippocampus of chronic unpredictable mild stress (CUMS) model rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Wild type male Sprague Dawley rat model of chronic unpredictable mild stress (CUMS) induced depression^[2].
Dosage:

2.2 mg/kg
Administration:

Intraperitoneal injection (i.p.); once a day; 28 days
Result:

Reversed the reduction of neurogenesis, GABAergic neurons, dendritic complexity, spinal density, and synaptic plasticity associated protein 95 (PSD95) by CUMS.

Chemical Information

CAS. Nr. 1421227-53-3
Appearance Solid
Molecular Weight 568.59
Formel C₂₉H₃₁F₃N₆O₃
Color White to light yellow
SMILES

O=C(NC1=CC=C(CN2CCN(C)CC2)C(C(F)(F)F)=C1)CC3=CC=C(OC4=NC=NC(NC(C5CC5)=O)=C4)C=C3
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (175.87 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7587 mL

8.7937 mL

17.5874 mL

5 mM

0.3517 mL

1.7587 mL

3.5175 mL

10 mM

0.1759 mL

0.8794 mL

1.7587 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Boerner BP, George NM, Mir SU, Sarvetnick NE. WS6 induces both alpha and beta cell proliferation without affecting differentiation or viability. Endocr J. 2015;62(4):379-86. [Content Brief]

[2]. Zhang H, et al. WS6 Induces Adult Hippocampal Neurogenesis in Correlation to its Antidepressant Effect on the Alleviation of Depressive-like Behaviors of Rats. Neuroscience. 2021 Oct 1;473:119-129. [Content Brief]

[3]. Massudi H, et al. Inhibitors of the Oncogenic PA2G4-MYCN Protein-Protein Interface. Cancers (Basel). 2023 Mar 17;15(6):1822. [Content Brief]

[4]. Bregante J, et al. Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia. Cancers (Basel). 2021 Dec 8;13(24):6181. [Content Brief]

[5]. Zhang J, et al. ERBB2 signaling drives supporting cell proliferation in vitro and apparent supernumerary hair cell formation in vivo in the neonatal mouse cochlea. Eur J Neurosci. 2018 Nov;48(10):3299-3316. [Content Brief]

[6]. Firdoos S, et al. In silico identification of novel stilbenes analogs for potential multi-targeted drugs against Alzheimer's disease. J Mol Model. 2023 Jun 14;29(7):209. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7587 mL	8.7937 mL	17.5874 mL	43.9684 mL
	5 mM	0.3517 mL	1.7587 mL	3.5175 mL	8.7937 mL
	10 mM	0.1759 mL	0.8794 mL	1.7587 mL	4.3968 mL
	15 mM	0.1172 mL	0.5862 mL	1.1725 mL	2.9312 mL
	20 mM	0.0879 mL	0.4397 mL	0.8794 mL	2.1984 mL
	25 mM	0.0703 mL	0.3517 mL	0.7035 mL	1.7587 mL
	30 mM	0.0586 mL	0.2931 mL	0.5862 mL	1.4656 mL
	40 mM	0.0440 mL	0.2198 mL	0.4397 mL	1.0992 mL
	50 mM	0.0352 mL	0.1759 mL	0.3517 mL	0.8794 mL
	60 mM	0.0293 mL	0.1466 mL	0.2931 mL	0.7328 mL
	80 mM	0.0220 mL	0.1099 mL	0.2198 mL	0.5496 mL
	100 mM	0.0176 mL	0.0879 mL	0.1759 mL	0.4397 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

WS6

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Membrane Transporter/Ion Channel Compound Library

Neuronal Signaling Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Neurotransmitter Receptor Compound Library

Anti-Alzheimer's Disease Compound Library

Neuroprotective Compound Library

Anti-Hepatitis C Virus Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Antidepressant Compound Library

GABA Receptor Compound Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Antihypertensive Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Serine/Threonine Kinase Inhibitor Library

Ion Channel Compound Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Lactylation Compound Library

Alle PI3K Isoform-spezifische Produkte anzeigen

Alle EGFR Isoform-spezifische Produkte anzeigen

Alle IKK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

WS6 Related Classifications

HY-12461 Related Classifications